logo
#

Latest news with #IncyteCorporation

JAK Inhibitors Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
JAK Inhibitors Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

Globe and Mail

time9 hours ago

  • Business
  • Globe and Mail

JAK Inhibitors Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, ' Janus Kinase (JAK) Inhibitor Pipeline Insight, 2025 ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the JAK Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the JAK Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the JAK Inhibitors Treatment Landscape. Click here to read more @ JAK Inhibitors Pipeline Outlook Key Takeaways from the JAK Inhibitors Pipeline Report In June 2025, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care. DelveInsight's JAK Inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for JAK Inhibitors treatment. The leading JAK Inhibitors Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Promising JAK Inhibitors Pipeline Therapies such as Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. Stay informed about the cutting-edge advancements in JAK Inhibitors Treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ JAK Inhibitors Clinical Trials Assessment JAK Inhibitors Emerging Drugs Profile Povorcitinib: Incyte Corporation Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo. CPL409116: Celon Pharma CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL'116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease. ATI-2138: Aclaris Therapeutics ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities. SDC 1802: Sareum SDC-1802 is an investigational Sareum's TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer. The JAK Inhibitors pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of JAK Inhibitors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for JAK Inhibitors Treatment. JAK Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. JAK Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the JAK Inhibitors market. Get a detailed analysis of the latest innovations in the JAK Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ JAK Inhibitors Unmet Needs JAK Inhibitors Companies Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical JAK Inhibitors Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in JAK Inhibitors Treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ JAK Inhibitors Market Drivers and Barriers, and Future Perspectives Scope of the JAK Inhibitors Pipeline Report Coverage- Global JAK Inhibitors Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. JAK Inhibitors Pipeline Therapies- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. JAK Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination JAK Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of JAK Inhibitors Pipeline on our website @ JAK Inhibitors Emerging Drugs and Companies Table of Contents Introduction Executive Summary Janus Kinase (JAK) Inhibitor: Overview Pipeline Therapeutics Therapeutic Assessment Janus Kinase (JAK) Inhibitor– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Povorcitinib: Incyte Corporation Drug profiles in the detailed report….. Mid Stage Products (Phase II) CPL409116: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) ATI-2138: Aclaris Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SDC 1802: Sareum Drug profiles in the detailed report….. Inactive Products Janus Kinase (JAK) Inhibitor Key Companies Janus Kinase (JAK) Inhibitor Key Products Janus Kinase (JAK) Inhibitor- Unmet Needs Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion Janus Kinase (JAK) Inhibitor Analyst Views Janus Kinase (JAK) Inhibitor Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects

Yahoo

time4 days ago

  • Business
  • Yahoo

Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects

Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a 'Neutral' rating on the stock and increased its price target to $62 from $61. A pharmacist preparing a dose of an immuno-oncology agent for research use. The price hike comes as UBS expects higher sales for Incyte's Niktimvo, a treatment for chronic Graft-versus-Host Disease (cGVHD). Amid the expected higher sales, UBS has revised its 2026 earnings per share estimate of $6.36 from $6.26. UBS also maintained a 9.5x price-to-earnings multiple on Incyte, as it expects the company's second-quarter earnings call to provide clarity on the company's strategic direction. The company's pipeline has already received a boost following the FDA's extension of the review for ruxolitinib cream for pediatric atopic dermatitis. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapies in oncology and inflammation & autoimmunity. It also boasts a growing portfolio of treatments for other diseases, including those in dermatology. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey.

Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment

Globe and Mail

time21-07-2025

  • Business
  • Globe and Mail

Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment

DelveInsight's, ' Glioma Pipeline Insight, 2025 ' report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Glioma Pipeline. Dive into DelveInsight's comprehensive report today! @ Glioma Pipeline Outlook Key Takeaways from the Glioma Pipeline Report In July 2025, Eli Lilly and Company announced a study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. In July 2025, Istari Oncology Inc. announced a Phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma. The objective of this study is to investigate the safety and efficacy (anti-tumor response and survival) of lerapolturev in recurrent WHO grade IV malignant glioma. In July 2025, Incyte Corporation conducted a study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal. In July 2025, Nuvation Bio Inc. organized a 2-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. DelveInsight's Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment. The leading Glioma Companies such as CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Promising Glioma Pipeline Therapies such as DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others. Stay ahead with the most recent pipeline outlook for Glioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Glioma Treatment Drugs Glioma Emerging Drugs Profile AV-GBM-1: Aivita Biomedical, Inc. AV-GBM-1 is an innovative immunotherapy developed by AIVITA Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells that are loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient's unique cancer profile. Currently, the drug is in phase III stage of its clinical trial for the treatment of Glioma. DB 107: Denovo BioPharma Denovo BioPharma's DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma. MDNA55: Medicenna Therapeutics, Inc. MDNA55 is a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma. Abemaciclib: Eli Lilly and Company Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. NMS-03305293: Nerviano Medical Sciences NMS-293 is a second generation PARP inhibitor that differentiates from other approved or advanced molecules in its unique selectivity for PARP1 vs. PARP2 enzymes and low DNA trapping activity, both features potentially linked to lower hematological toxicity and higher potential for combination with DNA damaging agents in a wide range of tumors, covering high unmet medical needs. It also has a superior ability to penetrate the blood-brain barrier, a very important feature supporting its utilization in CNS tumors and brain metastases. The drug has shown high anti-tumor activity as single agent in BRCA mutated preclinical tumor models and synergy and tolerability in combination with chemotherapy. Based on the findings, NMS-293 is currently in clinical developmental Phase II in combination with temozolomide in recurrent glioblastoma. CAN-3110: Candel Therapeutics CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase I investigator-sponsored clinical trial in patients with recurrent HGG. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioma. MB-101: Mustang Bio MB-101 is an IL13Rα2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. Currently, the drug is in Phase I stage of clinical trial for the treatment of Glioma. The Glioma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Glioma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma Treatment. Glioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market Explore groundbreaking therapies and clinical trials in the Glioma Pipeline. Access DelveInsight's detailed report now! @ New Glioma Drugs Glioma Companies CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Glioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Glioma Products have been categorized under various Molecule types, such as Oligonucleotide Peptide Small molecule Unveil the future of Glioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Glioma Market Drivers and Barriers Scope of the Glioma Pipeline Report Coverage- Global Glioma Companies- CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Glioma Pipeline Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others. Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Glioma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Glioma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Glioma Disease: Overview Pipeline Therapeutics Therapeutic Assessment Glioma Disease– DelveInsight's Analytical Perspective Late Stage Products (Phase III) AV-GBM-1: Aivita Biomedical, Inc. Drug profiles in the detailed report….. Mid Stage Products (Phase II) DB 107: Denovo BioPharma Drug profiles in the detailed report….. Early Stage Products (Phase I) MB-101: Mustang Bio Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Glioma Disease Key Companies Glioma Disease Key Products Glioma Disease- Unmet Needs Glioma Disease- Market Drivers and Barriers Glioma Disease- Future Perspectives and Conclusion Glioma Disease Analyst Views Glioma Disease Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions

Yahoo

time22-06-2025

  • Business
  • Yahoo

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions

Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy. On June 17, Incyte was a big mover in the market, announcing the signing of a strategic partnership with Netherlands QIAGEN N.V. QGEN. The two are coming together to enhance the development of a novel diagnostic panel to support investigational treatments for myeloproliferative neoplasms (MPNs). A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug. The strategic partnership covers the development of Incyte's investigational monoclonal antibody targeting mutant calreticulin (mutCALR), currently under development for myelofibrosis (MF) and essential thrombocythemia (ET). The deal is also expected to benefit Incyte in advancing its precision medicine efforts in MPNs. Under the terms of the agreement, QIAGEN is to develop a multimodal panel using next-generation sequencing (NGS) technology. The panel aims to identify key gene alterations in MPNs. The panel will also be validated on the Illumina NextSeq 550Dx platform for use with whole blood samples. Incyte Corporation (NASDAQ:INCY) is a global biopharmaceutical company that focuses on discovering, developing, and commercializing proprietary therapeutics for patients with unmet medical needs. It develops drugs for rare and hard-to-treat diseases, including those in oncology and inflammation/autoimmunity. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store